NASDAQ:CCCC

C4 Therapeutics Stock Insider Trading

Healthcare > Biotechnology

Buy CCCC

*Your capital is at risk

$3.92

-0.140 (-3.45%)

At Close: Jul 13, 2026

C4 Therapeutics Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 88.01. In total, the insiders bought 4.17M and sold 184.38K CCCC shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	88.01
● Buy	4.17M shares
● Sell	184.38K shares
75% Buy Activity Moderate Negative Correlation
Buy Signal Medium Confidence Jun 24, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 88.01. Confidence increased due to high data reliability score of 100.

Historical Insider Trades

Date	Type	Person	Role	Amount
Jul 10, 2026 Buy	Common Stock M-Exempt	Reyno Leonard Chief Medical Officer	Officer	15 325 Value: $62.2K
Jul 10, 2026 Sell	Common Stock F-InKind	Reyno Leonard Chief Medical Officer	Officer	7 397 Value: $30.0K
Jul 01, 2026 Buy	Common Stock A-Award	Anderson Kenneth Carl Director	Director	2 650 Value: $11.5K
Jul 01, 2026 Buy	Common Stock A-Award	Grogan Donna Roy Director	Director	3 341 Value: $14.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Hughes Owen Director	Director	62 000 Value: $263.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Hoerter Steven L. Director	Director	62 000 Value: $263.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Koppikar Utpal Director	Director	62 000 Value: $263.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Anderson Kenneth Carl Director	Director	62 000 Value: $263.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Cooper Ronald Harold Wilfred Director	Director	62 000 Value: $263.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Bessen Laura Director	Director	62 000 Value: $263.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Fawell Stephen Director	Director	62 000 Value: $263.5K
Jun 24, 2026 Buy	Stock Option (Right to Buy) A-Award	Grogan Donna Roy Director	Director	62 000 Value: $263.5K
Jun 01, 2026 Buy	Common Stock M-Exempt	Anderson Kenneth Carl Director	Director	1 070 Value: $2K
Jun 01, 2026 Buy	Stock Option (Right to Buy) M-Exempt	Anderson Kenneth Carl Director	Director	1 070 Value: $2K
Apr 01, 2026 Buy	Common Stock A-Award	Anderson Kenneth Carl Director	Director	4 259 Value: $11.5K
Apr 01, 2026 Buy	Common Stock A-Award	Grogan Donna Roy Director	Director	5 370 Value: $14.5K
Feb 15, 2026 Sell	Common Stock F-InKind	Hirsch Andrew President & CEO	CEO / President	9 057 Value: $17.1K
Feb 15, 2026 Buy	Common Stock M-Exempt	Hirsch Andrew President & CEO	CEO / President	20 400 Value: $80.0K
Feb 14, 2026 Buy	Common Stock M-Exempt	Mossler Mark Chief Accounting Officer	Officer	9 420 Value: $36.9K
Feb 14, 2026 Sell	Common Stock F-InKind	Adams Kendra Chief Financial Officer	C-Suite Officer	15 381 Value: $29.1K
Feb 14, 2026 Buy	Common Stock M-Exempt	Adams Kendra Chief Financial Officer	C-Suite Officer	30 950 Value: $121.3K
Feb 14, 2026 Sell	Common Stock F-InKind	Reyno Leonard Chief Medical Officer	Officer	16 579 Value: $31.3K
Feb 14, 2026 Buy	Common Stock M-Exempt	Reyno Leonard Chief Medical Officer	Officer	30 950 Value: $121.3K
Feb 14, 2026 Sell	Common Stock F-InKind	Hirsch Andrew President & CEO	CEO / President	39 154 Value: $74.0K
Feb 14, 2026 Buy	Common Stock M-Exempt	Hirsch Andrew President & CEO	CEO / President	81 725 Value: $320.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT C4 THERAPEUTICS INC

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma an...

Read Full Profile Here